ClinicalTrials.gg
Active, not recruitingNCT04950322Updated Mar 30, 2025

A Trial of SHR1701 Plus Chemotherapy in Patients With Gastric or Gastroesophageal Cancer

A Phase 3 interventional study of SHR-1701、CAPOX and Placebo、CAPOX in Gastric or Gastroesophageal Junction Cancer, sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-30.

Sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
737
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is a randomized, Double-Blind, multi-center Phase III clinical study, aimed to evaluate the efficacy and safety of SHR1701 combined with chemotherapy in the treatment of Previously Untreated, Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer. For Part 1 study,the tolerability of SHR-1701 will be evaluated and determine the recommended dose for Part 2.For Part 2 study, all enrolled patients will be randomized to 2 groups and continuously treated until the end criteria of treatment was met.

02

Conditions studied

  • Gastric or Gastroesophageal Junction Cancer
03

In context

Lead sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd. is the lead sponsor of 104 studies on the registry; 73 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed diagnosis of locally advanced unresectable or gastric or gastroesophageal junction (GEJ)adenocarcinoma.
  2. overexpression or amplification negative.
  3. Female or male, 18 years of age or above.
  4. (ECOG) performance status of 0 - 1.
  5. Patients who are willing and able to provide the signed form, willing and able to comply with all the scheduled visits, study treatment, laboratory tests, and other study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Squamous cell carcinoma, undifferentiated carcinoma, or other histological types of gastric cancer.
  2. Presence of inadequately treated , or uncontrolled or symptomatic active CNS metastases ,, and/or rapid progression.
  3. Presence of uncontrolled pleural effusion or ascites despite puncture drainage within 14 days prior to randomization.
  4. More than 20% weight loss within 2 months prior to randomization.
  5. Diagnosed with other malignant tumors within 5 years prior to enrollment.
  6. Presence of any active, known or suspected disease.
  7. Prior treatment with TGF-β inhibitor, /PD-L1 antibodies, anti-PD-L2 antibodies, anti-CD137 antibodies, anti-CTLA-4 antibodies, or other drugs/antibodies.
  8. Severe, unhealed, or dehisced wounds and active ulcers or untreated fractures.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
737 participants (actual)

Study arms

  • Experimental
    Treatment group A

    Drug: SHR-1701、CAPOX

  • Placebo comparator
    Treatment group B

    Drug: Placebo、CAPOX

Interventions

  • DrugSHR-1701、CAPOX

    SHR-1701 with CAPOX (CAPOX:Oxaliplatin,Capecitabine)

  • DrugPlacebo、CAPOX

    Placebo with CAPOX (CAPOX:Oxaliplatin,Capecitabine)

06

What researchers measure

Primary outcomes

  1. AEs and SAEs in part 1 study

    The number and proportion of subjects with dose limiting toxicity. The safety endpoints, including incidence and severity of adverse events (AEs) and serious adverse events (SAEs).

    Time frame: up to 2 years

  2. Overall survival in subjects with PD-L1 CPS ≥ 5 in part 2 study

    Time frame: up to 3 years

  3. OS in all subjects in part 2 study

    Overall survival (OS)

    Time frame: up to 3 years

Secondary outcomes

  1. ORR in part 1 study

    Objective response rate (ORR) as assessed by the investigator per RECIST 1.1

    Time frame: up to 2 years

  2. DCR in part 1 study

    Disease control rate (DCR) as assessed by the investigator per RECIST 1.1

    Time frame: up to 2 years

  3. PFS in part 1 study

    Progression free survival (PFS) as assessed by the investigator per RECIST 1.1

    Time frame: up to 2 years

  4. DoR in part 1 study

    Duration of response (DoR) as assessed by the investigator per RECIST 1.1

    Time frame: up to 2 years

  5. OS in part 1 study

    Overall survival (OS)

    Time frame: up to 3 years

  6. PFS in part 2 study

    PFS in subjects with PD-L1 CPS ≥5 and in all subjects as assessed by BICR per RECIST 1.1

    Time frame: up to 3 years

  7. ORR in part 2 study

    ORR in subjects with PD-L1 CPS ≥5 and in all subjects as assessed by BICR per RECIST 1.1

    Time frame: up to 2 years

  8. DCR in part 2 study

    DCR in subjects with PD-L1 CPS ≥5 and in all subjects as assessed by BICR per RECIST 1.1

    Time frame: up to 2 years

  9. DoR in part2 study

    DoR in subjects with PD-L1 CPS ≥5 and in all subjects as assessed by BICR per RECIST 1.1

    Time frame: up to 2 years

  10. PFS in subjects with PD-L1 CPS ≥5 and in all subjects as assessed by investigator as per RECIST 1.1

    Time frame: up to 2 years

  11. ORR in part 2 study

    ORR in subjects with PD-L1 CPS ≥5 and in all subjects as assessed by investigator per RECIST 1.1

    Time frame: up to 2 years

  12. DCR in part 2 study

    DCR in subjects with PD-L1 CPS ≥5 and in all subjects as assessed by investigator per RECIST 1.1

    Time frame: up to 2 years

  13. DoR in part 2 study

    DoR in subjects with PD-L1 CPS ≥5 and in all subjects as assessed by investigator per RECIST 1.1

    Time frame: up to 2 years

  14. AEs and SAEs in part 2 study

    Safety endpoints, including incidence and severity of AEs and SAEs as per NCI-CTCAE v5.0 criteria

    Time frame: up to 2 years

  15. EORTC QLQ-C30 score

    Time frame: up to 2 years

  16. EORTC QLQ-STO22 score

    Time frame: up to 2 years

  17. EQ-5D-5L score

    Time frame: up to 2 years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2021 to primary completion in May 2024, 29 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2021
First posted
Jul 6, 2021
StartActual
Dec 6, 2021
Primary completionActual
May 20, 2024
CompletionEst.
Oct 1, 2025
Last update
Mar 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04950322
Responsible party
Sponsor
First posted
Jul 6, 2021
Start date
Dec 6, 2021
Primary completion
May 20, 2024
Completion
Oct 1, 2025 (estimated)
Last update
Mar 30, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion